The promise of our targets
We approach discovery with an entrepreneurial spirit and choose to pursue targets based on where we believe the science will take us in the next decade, not just a few years from now. Our clinical research and development spans multiple areas, including oncogenic pathways, survival mechanisms, and novel protein interactions.
We invite you to explore our current focus areas below:
Redox balance and pSTAT3
The prognostic value of pSTAT3 in cancer may be connected to redox balance.Learn more
CDK9 inhibition may be a therapeutic strategy for some MCL-1-dependent hematologic malignancies.See more
Wilms’ Tumor 1 (WT1)
WT1 is a highly prioritized tumor antigen that may be a candidate for immunotherapy approaches.Learn more